Abstract
Three groups of rabbits differing in terms of movement activity in an open field (active, passive, and intermediate animals) were used to study the effects of systemic administration of the GABA receptor agonist phenibut (40 mg/kg, s.c.) on behavior in the open field, behavioral reactivity, and changes in measures of respiration during exposure to emotionally negative stimuli. Phenibut administration led to decreases in horizontal movement activity and some elements of investigative behavior in rabbits in the open field, along with decreases in the reactivity of the animals to emotionally significant stimuli. There were reductions in the probabilities of both active (orientational-investigative, active defensive) and passive defensive (freezing) reactions. The effects of phenibut depended on the typological characteristics of the rabbits: its actions on behavior were most marked in active rabbits and were less marked in passive animals; phenibut had virtually no effect on the behavior of intermediate rabbits. The duration of inhalation by the rabbits on exposure to emotionally significant stimuli increased after phenibut, which contrasted with a reduction seen in normal animals; this is evidence for changes in the autonomic reactivity of the animals.
Similar content being viewed by others
References
I. V. Belozertseva and B. V. Andreev, “Pharmaco-ethological studies of the GABAergic mechanisms of regulation of depression-like behavior in mice,” Zh. Vyssh. Nerv. Deyat., 47, No. 4, 1024–1031 (1997).
A. V. Val’dman, M. M. Kozlovskaya, and O. O. Medvedev, Pharmacological Regulation of Emotional Stress [in Russian], Meditsina, Moscow (1979).
J. Grey, “Neuropsychology of emotions and personality structure,” Zh. Vyssh. Nerv. Deyat., 37, No. 6, 1011–1024 (1987).
E. A. Zyablitseva, “Effects of the GABA derivative phenibut on the acquisition of a defensive conditioned reflex and internal inhibition,” Zh. Vyssh. Nerv. Deyat., 56, No. 2, 236–241 (2006).
I. P. Lapin, Personality and Therapeutic Drugs. An Introduction to the Psychology of Pharmacotherapy [in Russian], Dean, St. Petersburg (2001).
M. D. Mashkovskii, Therapeutic Agents [in Russian], Novaya Volna, Moscow (2000), Vol. 1.
I. V. Pavlova, I. P. Levshina, G. L. Vanetsian, N. N. Shuikin, and E. A. Zyablitseva, “Behavior and respiratory characteristics in rabbits with different levels of movement activity in the open field,” Ros. Fiziol. Zh., 91, No. 9, 1021–1032 (2005).
I. V. Pavlova, I. P. Levshina, G. L. Vanetsian, Yu. V. Pavlov, N. N. Shuikin, and E. A. Zyablitseva, “Effects of emotionally significant stimuli on behavior and respiration in rabbits with different levels of movement activity in an open field,” Zh. Vyssh. Nerv. Deyat., 56, No. 1, 64–73 (2006).
A. N. Talalaenko, T. K. Krivobok, Yu. V. Babii, V. A. Bogdanov, and N. S. Perch, “Neurochemical mechanisms of the central nucleus of the amygdaloid complex and the anxiolytic actions of tranquillizers in different models of anxious states,” Zh. Vyssh. Nerv. Deyat., 44, No. 6, 1116–1123 (1994).
I. A. Tarakanov and V. A. Safonov, “Effects of phenibut on the formation of the respiratory rhythm,” Byull. Éksperim. Biol. Med., 119, No. 6, 606–609 (1995).
I. A. Tarakanov and V. A. Safonov, “The GABAergic system and its role in the regulation of respiration,” Fiziol. Cheloveka, 24, No. 5, 116–128 (1998).
R. A. Khaunina, “The tranquillizing effects of β-phenyl-γ-aminobutyric acid (Fenigam),” Byull. Éksperim. Biol. Med., 57, No. 1, 54–58 (1964).
R. A. Khaunina and I. P. Lapin, “Use of phenibut in psychiatry and neurology and its place among other psychotropic substances,” Zh. Nevrol. Psikhiatr., 89, No. 4, 142–151 (1989).
G. I. Shul’gina, A. P. Petrishcheva, and G. G. Kuznetsova, “Effects of the GABA derivative phenibut on behavior and visual cortex neuron activity in rabbits during acquisition of a defensive reflex and internal inhibition,” Zh. Vyssh. Nerv. Deyat., 35, No. 4, 695–702 (1985).
J. T. Atack, K. A. Wafford, S. J. Tye, S. M. Cook, B. Sohal, A. Pike, C. Sur, D. Melill, L. Bristow, F. Bromidge, I. Ragan, J. Kerby, L. Street, R. Carling, J. L. Castro, P. Whiting, G. R. Dawson, and R. M. McKernan, “TPA023 [7-(1.1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluoropheny 1)-1,2,4-triazolo[4,3-b]pyridazine], an agonist selective for alpha2-and alpha3-containing GABAA receptors, is a nonsedating anxiolytic in rodents and primates,” J. Pharmacol. Exptl. Ther., 316, No. 1, 410–422 (2006).
H. Carm A. Nadlewska, R. Oksztel, and K. Wiszniewski, “AI-DA influences behavior in rats pretreated with baclofen,” Pol. J. Pharmacol., 53, No. 3, 245–252 (2001).
J. N. Crawley, “Exploratory behavior models of anxiety in mice,” Neurosci. Biobehav. Rev., 9, No. 1, 37–44 (1985).
A. Degroot, S. Kashluba, and D. Treit, “Septal GABAergic and hippocampal cholinergic systems modulate anxiety in the plus-maze and shock-probe tests,” Pharmacol. Biochem. Behav., 69, No. 3–4, 391–399 (2001).
R. K. McNamara and R. W. Skelton, “Baclofen, a selective GABAB receptor agonist, dose-dependently impairs spatial learning in rats,” Pharmacol. Biochem. Behav., 53, No. 2, 303–308 (1996).
J. Mos, B. Olivier, and A. M. van der Poel, “Modulatory actions of benzodiazepine receptor ligands on agonistic behaviour,” Physiol. Behav., 41, No. 3, 265–278 (1987).
M. Nazar, M. Siemiatkowski, A. Czlonkowska, H. Sienkiewicz-Jarosz, and A. Plasnik, “The role of the hippocampus and 5-HT/GABA interaction in the central effects of benzodiazepine receptor ligands,” J. Neural Transm., 106, No. 5–6, 369–381 (1999).
M. Van Nobelen and L. Kokkinidis, “GABA, not glutamate neurotransmission or mRNA transcription controls footshock-associated fear arousal in the acoustic startle paradigm,” Neurosci., 137, No. 2, 707–716 (2006).
R. Oksztel, H. Car, and K. Wisniewski, “Muscimol changes hypoxia-induced impairment of behavior in rats,” Pol. J. Pharmacol., 54, No. 5, 423–431 (2002).
P. G. Osborne, “A GABAergic mechanism in the medial septum influences cortical arousal and locomotor activity but not a previously learned spatial discrimination task,” Neurosci. Lett., 173, No. 1–2, 63–66 (1994).
L. Rago, R. A. Kiivet, J. Harro, and M. Pold, “Behavioral differences in an elevated plus-maze: correlation between anxiety and decreased number of GABA and benzodiazepine receptors in mouse cerebral cortex,” Naunyn. Schmiederbergs. Arch. Pharmacol., 337, No. 6, 675–678 (1988).
V. B. Risbrough, J. D. Brodkin, and M. A. Geyer, “GABAA and 5-HT1A receptor agonists block expression of fear-potentiated startle in mice,” Neuropsychopharmacology, 28, No. 4, 654–663 (2003).
M. B. Ruarte and E. O. Alvarez, “Behavioral profiles displayed by rats in an elevated asymmetric plus-maze: effects of diazepam,” Braz. J. Med. Biol. Res., 32, No. 1, 99–106 (1999).
A. S. Russo, F. S. Guimaraes, J. C. de Aguiar, and F. G. Graeff, “Role of benzodiazepine receptors located in the dorsal periaque-ductal grey of rats in anxiety,” Psycopharmacology, 110, No. 1–2, 198–202 (1993).
M. L. Scottoni, G. Calamandrei, and L. Ricceri, “Neonatal cholinergic lesions and development of exploration upon administration of the GABAA receptor agonist muscimol in preweaning rats,” Pharmacol. Biochem. Behav., 76, No. 2, 213–221 (2003).
A. A. Shah, T. Sjovold, and D. Treit, “Inactivation of the medial prefrontal cortex with the GABAA receptor agonist muscimol increases open-arm activity in the elevated plus-maze and attenuates shock-probe burying in rats,” Brain Res., 1028, No. 1, 112–115 (2004).
Author information
Authors and Affiliations
Corresponding author
Additional information
__________
Translated from Zhurnal Vysshei Nervnoi Deyatel’nosti imeni I. P. Pavlova, Vol. 57, No. 4, pp. 479–488, July–August, 2007.
Rights and permissions
About this article
Cite this article
Zyablitseva, E.A., Pavlova, I.V. Effects of the GABA receptor agonist phenibut on behavior and respiration in rabbits in emotionally negative situations. Neurosci Behav Physi 38, 555–562 (2008). https://doi.org/10.1007/s11055-008-9025-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11055-008-9025-2